vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Koppers Holdings Inc. (KOP). Click either name above to swap in a different company.
Koppers Holdings Inc. is the larger business by last-quarter revenue ($432.7M vs $281.3M, roughly 1.5× Guardant Health, Inc.). Koppers Holdings Inc. runs the higher net margin — 6.9% vs -45.7%, a 52.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -9.3%). Koppers Holdings Inc. produced more free cash flow last quarter ($28.5M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -6.7%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Koppers is a global chemical and materials company based in Pittsburgh, Pennsylvania, United States. Its headquarters is an art-deco 1920s skyscraper, the Koppers Tower.
GH vs KOP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $432.7M |
| Net Profit | $-128.5M | $29.7M |
| Gross Margin | 64.6% | 25.6% |
| Operating Margin | -43.0% | 11.5% |
| Net Margin | -45.7% | 6.9% |
| Revenue YoY | 39.4% | -9.3% |
| Net Profit YoY | -15.8% | 391.2% |
| EPS (diluted) | $-1.01 | $1.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $432.7M | ||
| Q3 25 | $265.2M | $485.3M | ||
| Q2 25 | $232.1M | $504.8M | ||
| Q1 25 | $203.5M | $456.5M | ||
| Q4 24 | $201.8M | $477.0M | ||
| Q3 24 | $191.5M | $554.3M | ||
| Q2 24 | $177.2M | $563.2M | ||
| Q1 24 | $168.5M | $497.6M |
| Q4 25 | $-128.5M | $29.7M | ||
| Q3 25 | $-92.7M | $23.8M | ||
| Q2 25 | $-99.9M | $16.4M | ||
| Q1 25 | $-95.2M | $-13.9M | ||
| Q4 24 | $-111.0M | $-10.2M | ||
| Q3 24 | $-107.8M | $22.8M | ||
| Q2 24 | $-102.6M | $26.8M | ||
| Q1 24 | $-115.0M | $13.0M |
| Q4 25 | 64.6% | 25.6% | ||
| Q3 25 | 64.7% | 24.1% | ||
| Q2 25 | 65.0% | 22.6% | ||
| Q1 25 | 63.3% | 23.2% | ||
| Q4 24 | 61.6% | 17.5% | ||
| Q3 24 | 61.1% | 21.9% | ||
| Q2 24 | 59.1% | 21.6% | ||
| Q1 24 | 61.2% | 19.3% |
| Q4 25 | -43.0% | 11.5% | ||
| Q3 25 | -37.3% | 10.7% | ||
| Q2 25 | -45.9% | 7.7% | ||
| Q1 25 | -54.6% | 5.9% | ||
| Q4 24 | -62.4% | 1.3% | ||
| Q3 24 | -61.3% | 9.0% | ||
| Q2 24 | -56.8% | 10.2% | ||
| Q1 24 | -59.2% | 7.0% |
| Q4 25 | -45.7% | 6.9% | ||
| Q3 25 | -35.0% | 4.9% | ||
| Q2 25 | -43.0% | 3.2% | ||
| Q1 25 | -46.8% | -3.0% | ||
| Q4 24 | -55.0% | -2.1% | ||
| Q3 24 | -56.3% | 4.1% | ||
| Q2 24 | -57.9% | 4.8% | ||
| Q1 24 | -68.2% | 2.6% |
| Q4 25 | $-1.01 | $1.44 | ||
| Q3 25 | $-0.74 | $1.17 | ||
| Q2 25 | $-0.80 | $0.81 | ||
| Q1 25 | $-0.77 | $-0.68 | ||
| Q4 24 | $-0.90 | $-0.47 | ||
| Q3 24 | $-0.88 | $1.09 | ||
| Q2 24 | $-0.84 | $1.25 | ||
| Q1 24 | $-0.94 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | $928.3M |
| Stockholders' EquityBook value | $-99.3M | $574.0M |
| Total Assets | $2.0B | $1.9B |
| Debt / EquityLower = less leverage | — | 1.62× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | — | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | — | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $1.5B | $928.3M | ||
| Q3 25 | $1.1B | $932.9M | ||
| Q2 25 | $1.1B | $977.5M | ||
| Q1 25 | $1.1B | $989.0M | ||
| Q4 24 | $1.1B | $939.5M | ||
| Q3 24 | — | $989.4M | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $877.6M |
| Q4 25 | $-99.3M | $574.0M | ||
| Q3 25 | $-354.5M | $545.6M | ||
| Q2 25 | $-305.5M | $526.8M | ||
| Q1 25 | $-250.8M | $498.0M | ||
| Q4 24 | $-139.6M | $488.7M | ||
| Q3 24 | $-60.1M | $532.3M | ||
| Q2 24 | $-1.6M | $509.2M | ||
| Q1 24 | $68.3M | $505.8M |
| Q4 25 | $2.0B | $1.9B | ||
| Q3 25 | $1.3B | $1.9B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $1.9B | ||
| Q4 24 | $1.5B | $1.9B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.6B | $1.9B | ||
| Q1 24 | $1.7B | $1.8B |
| Q4 25 | — | 1.62× | ||
| Q3 25 | — | 1.71× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | — | 1.97× | ||
| Q1 24 | — | 1.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $45.1M |
| Free Cash FlowOCF − Capex | $-54.2M | $28.5M |
| FCF MarginFCF / Revenue | -19.3% | 6.6% |
| Capex IntensityCapex / Revenue | 9.9% | 3.8% |
| Cash ConversionOCF / Net Profit | — | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $67.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $45.1M | ||
| Q3 25 | $-35.4M | $49.6M | ||
| Q2 25 | $-60.3M | $50.5M | ||
| Q1 25 | $-62.7M | $-22.7M | ||
| Q4 24 | $-64.5M | $74.7M | ||
| Q3 24 | $-51.1M | $29.8M | ||
| Q2 24 | $-94.0M | $27.2M | ||
| Q1 24 | $-30.3M | $-12.3M |
| Q4 25 | $-54.2M | $28.5M | ||
| Q3 25 | $-45.8M | $37.6M | ||
| Q2 25 | $-65.9M | $38.4M | ||
| Q1 25 | $-67.1M | $-37.0M | ||
| Q4 24 | $-83.4M | $56.1M | ||
| Q3 24 | $-55.3M | $14.4M | ||
| Q2 24 | $-99.1M | $10.1M | ||
| Q1 24 | $-37.2M | $-38.6M |
| Q4 25 | -19.3% | 6.6% | ||
| Q3 25 | -17.3% | 7.7% | ||
| Q2 25 | -28.4% | 7.6% | ||
| Q1 25 | -33.0% | -8.1% | ||
| Q4 24 | -41.3% | 11.8% | ||
| Q3 24 | -28.9% | 2.6% | ||
| Q2 24 | -55.9% | 1.8% | ||
| Q1 24 | -22.1% | -7.8% |
| Q4 25 | 9.9% | 3.8% | ||
| Q3 25 | 3.9% | 2.5% | ||
| Q2 25 | 2.4% | 2.4% | ||
| Q1 25 | 2.2% | 3.1% | ||
| Q4 24 | 9.4% | 3.9% | ||
| Q3 24 | 2.2% | 2.8% | ||
| Q2 24 | 2.9% | 3.0% | ||
| Q1 24 | 4.1% | 5.3% |
| Q4 25 | — | 1.52× | ||
| Q3 25 | — | 2.08× | ||
| Q2 25 | — | 3.08× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | 1.01× | ||
| Q1 24 | — | -0.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
KOP
| Other | $127.8M | 30% |
| Railroad Treated Products | $119.0M | 28% |
| Utility Poles | $79.8M | 18% |
| Pitch And Related Products | $74.1M | 17% |
| Carbon Black Feedstock And Distillates | $14.4M | 3% |
| Railroad Infrastructure Products And Services | $9.9M | 2% |
| Phthalic Anhydride Naphthalene And Other Chemicals | $7.7M | 2% |
